Shortage of antidiabetic and antihypertensive in the context of the initial stage of the COVID-19 pandemic in Peru

• Autores: Herrera-Añazco, Percy, Valenzuela-Rodríguez, Germán, Torres-Pesantes, Luciana, Toro-Huamanchumo, Carlos J.
• Formato: artículo
• Fecha de Publicación: 2021
• Institución: Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
• Repositorio: Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
• Lenguaje: español
• OAI Identifier: oai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/1152
• Enlace del recurso: https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/1152
• Nivel de acceso: acceso abierto
• Materia: Antihipertensivos; Antidiabéticos; Accesibilidad a los Servicios de Salud; establecimientos de salud; Antihypertensive Agents; Hypoglycemic Agents; Health Services Accessibility; Health Facilities

Background: An adequate supply of medicines in health establishments will increase the possibility of adequate control of hypertension and diabetes. Objective: To determine the shortage of antidiabetic and antihypertensive drugs at the national level in the context of the initial stage of the COVID-19 pandemic in Peru. Material y methods: Analysis of the “Sistema Integrado de Suministro de Medicamentos e Insumos Médicos Quirúrgicos” (SISMED) Database, between June 13th and July 15th, 2020, according to the “National list for medicines of essential medicines” (PNUME) of Ministry of health. Results: and between 4 and 96% of the departments have a total shortage of at least one antidiabetic, and 4% and 96% of at least one antihypertensive. The most depleted antidiabetic was Metformin 500 mg, and the most depleted antihypertensive drugs were Labetalol 5 mg / ml iny, Atenolol 50 mg tab and Carvedilol 6.25 mg tab. The percentage of distribution was higher in hospitals and specialized institutes in comparison with primary health facilities. Conclusions: There is a shortage of antihypertensive and antidiabetic drugs in health centers in Peru.